Welcome to our dedicated page for Avinger news (Ticker: AVGR), a resource for investors and traders seeking the latest updates and insights on Avinger stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avinger's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avinger's position in the market.
Avinger, Inc. (NASDAQ:AVGR) has announced the full exercise of the underwriters' option to purchase an additional 2,368,421 shares at $0.38 each, raising approximately $6.9 million in total gross proceeds from its public offering. This funding will support Avinger's operations in developing its intravascular image-guided systems for Peripheral Artery Disease (PAD), which affects over 12 million people in the U.S. alone. Aegis Capital Corp. acted as the sole bookrunner for the offering.
Aegis Capital Corp. has successfully acted as the Sole Bookrunner for a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR). Avinger specializes in developing innovative solutions for the treatment of Peripheral Artery Disease (PAD), affecting over 12 million people in the U.S. and more than 200 million globally. Their unique Lumivascular platform includes advanced imaging and catheter technologies, aiming to transform PAD treatment.
Aegis Capital Corp. has successfully acted as the Sole Bookrunner for a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR), a company specializing in medical devices for Peripheral Artery Disease (PAD). Avinger's innovative Lumivascular platform aims to transform vascular disease treatment with its unique catheter-based systems, beneficial for the estimated 12 million people in the U.S. affected by PAD. The offering highlights Avinger's ongoing commitment to improving patient care in this growing market.